The European Medicines Agency has announced the start of a new review of the cardiovascular risks associated with the use of non-selective NSAIDs (non-steroidal anti-inflammatory drugs) which are used to treat pain and inflammation. ---Subscribe to MedNous to access this article--- Regulation & Policy
